What we know and don't know about the bioeffects of nanoparticles: developing experimental approaches for safety assessment.
Biomed Microdevices
; 12(4): 569-73, 2010 Aug.
Article
em En
| MEDLINE
| ID: mdl-19052876
ABSTRACT
The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA) regulates nano-based medical products and therefore is required to address the safety and biological effects of nano-scale materials used in these products. Both in vitro and in vivo toxicological research studies are being conducted at the FDA to help determine the risks versus benefits of these new products. This article will briefly summarize some of the initial research findings from FDA-CDRH studies using TiO(2), polystyrene, and silicon nanoparticles.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Toxicologia
/
Nanopartículas
Limite:
Animals
/
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Biomed Microdevices
Assunto da revista:
ENGENHARIA BIOMEDICA
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Estados Unidos